| Literature DB >> 34678909 |
Chisom Ogochukwu Ezenwaji1, Henry Egi Aloh2, Polycarp M D Okeke3, Chioma C Osilike3, Nwakaego Ebele Ekwealor3, Uzoamaka Lucynda Koledoye3, Leonard Chidi Ilechukwu4, Charles Chibuike Onwuadi3.
Abstract
BACKGROUND/Entities:
Mesh:
Year: 2021 PMID: 34678909 PMCID: PMC8542125 DOI: 10.1097/MD.0000000000027596
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Demographic characteristics of the participants.
| Characteristic | REBEI group, | No-contact group, | χ2 | Significance |
| Gender | ||||
| Male | 17 (19.8%) | 15 (17.4%) | .199 | .824 |
| Female | 26 (30.2%) | 28 (32.6%) | ||
| Agea | 22.14 ± 2.98 | 22.53 ± 3.02 | −.611 | .543∗ |
| Year of study | ||||
| First yr | 12 (14.0%) | 7 (8.1%) | 2.594 | .458 |
| Second yr | 18 (20.9%) | 17 (19.8%) | ||
| Third yr | 7 (8.1%) | 9 (10.5%) | ||
| Final yr | 6 (11.4%) | 10 (11.6%) | ||
| Mode of study | ||||
| Sandwich | 32 (37.2%) | 31 (36.0%) | .059 | .808 |
| Regular | 11 (12.8%) | 12 (14.0%) | ||
Results on the effects of group REBEI on social anxiety as measured by SAS-A.
| Time | SAS-A Subscale | Group | N | M | SD | 95% CI |
| ηp2 |
| Time 1 | FNE | Treatment | 43 | 30.05 | 1.48 | 29.59–30.50 | .571 | .004 |
| Control | 43 | 29.86 | 1.55 | 29.38–30.34 | ||||
| SAD-New | Treatment | 43 | 22.30 | 1.52 | 21.83–22.77 | .164 | .023 | |
| Control | 43 | 22.79 | 1.70 | 22.27–23.31 | ||||
| SAD-General | Treatment | 43 | 14.79 | 1.30 | 14.39–15.19 | .061 | .041 | |
| Control | 43 | 16.28 | 1.08 | 14.95–15.61 | ||||
| OVERALL | Treatment | 43 | 67.14 | 2.88 | 66.25–68.02 | .215 | .018 | |
| Control | 43 | 67.93 | 3.00 | 67.01–68.85 | ||||
| Time 2 | FNE | Treatment | 43 | 13.28 | 3.76 | 12.12–14.44 | <.001 | .845 |
| Control | 43 | 29.72 | 3.35 | 28.69–30.75 | ||||
| SAD-New | Treatment | 43 | 11.19 | 2.46 | 10.43–11.94 | <.001 | .849 | |
| Control | 43 | 22.81 | 2.50 | 22.04–23.58 | ||||
| SAD-General | Treatment | 43 | 6.77 | 2.02 | 6.15–7. 39 | <.001 | .858 | |
| Control | 43 | 15.33 | 1.46 | 14.88–15.77 | ||||
| OVERALL | Treatment | 43 | 31.23 | 7.46 | 28.94–33.53 | <.001 | .886 | |
| Control | 43 | 67.86 | 5.74 | 66.09–69.63 | ||||
| Time 3 | FNE | Treatment | 43 | 13.65 | 4.10 | 12.39–14.91 | <.001 | .830 |
| Control | 43 | 29.47 | 3.06 | 28.52–30.41 | ||||
| SAD-New | Treatment | 43 | 10.47 | 3.19 | 9.48–11.45 | <.001 | .828 | |
| Control | 43 | 22.67 | 2.38 | 21.94–23.41 | ||||
| SAD-General | Treatment | 43 | 6.88 | 1.55 | 6.41–7.36 | <.001 | .809 | |
| Control | 43 | 14.47 | 2.13 | 13.81–15.12 | ||||
| OVERALL | Treatment | 43 | 31.00 | 7.49 | 28.70–33.31 | <.001 | .882 | |
| Control | 43 | 66.60 | 5.56 | 64.89–68.32 |
Paired-samples t-test results on the effects of group REBEI on social anxiety as measured by SAS-A.
| Mean | SD | Std. error mean | t | df | Significant | |
| Pair 1 | ||||||
| Pretest-treatment | 67.14 | 2.88 | .43844 | 29.544 | 42 | .001 |
| Posttest-treatment | 31.23 | 7.46 | 1.13723 | |||
| Pair 2 | ||||||
| Posttest-treatment | 31.23 | 7.46 | 1.13723 | .419 | 42 | .678 |
| Follow-up-treatment | 31.00 | 7.49 | 1.14216 | |||
| Pair 3 | ||||||
| Pretest-control | 67.93 | 2.99 | .45676 | .069 | 42 | .945 |
| Posttest-control | 67.86 | 5.74 | .87577 | |||
| Pair 4 | ||||||
| Posttest-control | 67.86 | 5.74 | .87577 | 1.074 | 42 | .289 |
| Follow-up-Control | 66.60 | 5.56 | .84786 | |||
Post-hoc tests with Bonferroni-Holm corrections for P values.
| (J) Time | Mean difference (I-J) | Std. error | Significanceb | 95% CI for difference | |
| 1 | 2 | 17.988∗ | .788 | <.001 | 16.063–19.914 |
| 3 | 18.733∗ | .770 | <.001 | 16.852–20.613 | |
| 2 | 1 | −17.988∗ | .788 | <.001 | −19.914–−16.063 |
| 3 | .744 | .647 | .760 | −.837–2.325 | |
| 3 | 1 | −18.733∗ | .770 | <.001 | −20.613–−16.852 |
| 2 | −.744 | .647 | .760 | −2.325–.8 37 |